利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.03 秒)

    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
    2.
    发明申请
    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. 审中-公开
    包含N-4-（3-吡啶基）-2嘧啶胺和化学治疗剂的组合。

    公开(公告)号：US20120283206A1

    公开(公告)日：2012-11-08

    申请号：US13551079

    申请日：2012-07-17

    申请人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    发明人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    IPC分类号： A61K31/506 ,  A61K31/675 ,  A61P37/06 ,  A61K31/704 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/506

    摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.

    摘要翻译： 一种治疗具有增殖性疾病或急性或慢性移植排斥反应的温血动物，特别是人的方法，包括向动物施用包含（a）N- {5- [4-（4-甲基 - 哌嗪子基） - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺和（b）选自抗肿瘤剂，特别是本文所定义的化学治疗剂和有效治疗急性或慢性的药物 移植排斥反应 包含如上定义的（a）和（b）和任选的至少一种用于同时，分开或顺序使用的药学上可接受的载体的组合，特别是用于延缓进展或治疗增殖性疾病，特别是实体肿瘤疾病。

    Inhibitors of the Mutant Form of Kit
    9.
    发明申请
    Inhibitors of the Mutant Form of Kit 有权
    试剂盒突变体形式的抑制剂

    公开(公告)号：US20070213317A1

    公开(公告)日：2007-09-13

    申请号：US10579586

    申请日：2004-11-17

    申请人： Elisabeth Buchdunger ,  Doriano Fabbro

    发明人： Elisabeth Buchdunger ,  Doriano Fabbro

    IPC分类号： A61K31/506 ,  A61K31/553

    CPC分类号： A61K31/553 ,  A61K31/502 ,  A61K31/506 ,  G01N2800/44

    摘要： The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.

    摘要翻译： 本发明涉及KIT依赖性疾病的治疗，其特征在于突变体形式的KIT，由此鉴定突变型KIT，并且施用选自Midostaurin，瓦他拉尼和化合物A的突变型KIT的合适的抑制剂。

    Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis
    10.
    发明申请
    Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis 审中-公开
    使用嘧啶基氨基苯甲酰胺衍生物治疗纤维化

    公开(公告)号：US20110124670A1

    公开(公告)日：2011-05-26

    申请号：US13054011

    申请日：2009-07-14

    申请人： Elisabeth Buchdunger ,  Paul W. Manley

    发明人： Elisabeth Buchdunger ,  Paul W. Manley

    IPC分类号： A61K31/506 ,  A61P11/00 ,  A61P1/16

    CPC分类号： A61K31/506 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to the use of a pyrimidylaminobenzamides of formula I wherein the radicals have the meanings as defined herein, or of a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of fibrosis, to the use of a pyrimidylaminobenzamides of formula I or pharmaceutically acceptable salt thereof in the treatment of fibrosis, to a method of treating warm-blooded animals including humans suffering from fibrosis by administering to a said animal in need of such treatment an effective dose of a pyrimidylaminobenzamide of formula I or a pharmaceutically acceptable salt thereof, and to combinations comprising (a) at least one pyrimidylaminobenzamides of formula I as and (b) at least one compound selected form AT1-receptor antagonists and ACE inhibitors and the use of such combinations in the treatment of fibrosis, in particular hepatic fibrosis.

    摘要翻译： 本发明涉及式I的嘧啶基氨基苯甲酰胺的用途，其中基团具有如本文所定义的含义或其药学上可接受的盐在制备用于治疗纤维化的药物组合物中的用途，使用嘧啶基氨基苯甲酰胺 式I或其药学上可接受的盐在治疗纤维化中的用途，涉及一种通过向需要这种治疗的所述动物施用有效剂量的式I的嘧啶基氨基苯甲酰胺或其药学上可接受的方法来治疗包括患有纤维化的人的温血动物 和（a）至少一种式I的嘧啶基氨基苯甲酰胺和（b）至少一种选自AT1受体拮抗剂和ACE抑制剂的化合物，以及这些组合在治疗纤维化中的用途，特别是 肝纤维化。